Δ-10-Tetrahydrocannabinol
Viewing r1.a1 — Oct 2, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Δ10-THC (Δ-10-tetrahydrocannabinol) is an emerging semi-synthetic cannabinoid of the terpenophenolic class. It is a positional isomer of Δ9-THC, distinguished by weaker receptor binding and an unusual pharmacological profile. Δ10-THC binds CB1 and CB2 receptors but functions as a CB1 antagonist in vitro, blocking rather than activating the primary cannabinoid receptor.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
No dose data on record for this route. The timings below are not a dose guide.
First produced as a byproduct of cannabinoid isomerization research by the Mechoulam group in 1984,[2] Δ10-THC received no pharmacological follow-up for over three decades. Its accidental rediscovery in 2020 during processing of wildfire-contaminated cannabis biomass launched it into the hemp-derived cannabinoid market.[3] It is now sold widely in the United States as vapes, edibles, and blended formulations, though multiple states have moved to restrict it.[4]
Subjective effects include mild euphoria, mental stimulation, relaxation, and reduced anxiety relative to Δ9-THC. The experience is described as clear-headed and energizing — closer to a sativa-type cannabis feel than the sedating character typical of other THC isomers. Tachycardia, agitation, and CNS depression are reported unsought effects, though most adverse data reflect mixed-cannabinoid exposures.[5]
No dependence data exist, and no lethal dose has been established — the compound's CB1 antagonist profile complicates standard cannabinoid risk assumptions. The primary risk is product quality: all commercial Δ10-THC is produced via CBD isomerization, a process known to generate uncharacterized byproducts.[6] No controlled human studies have been conducted; the current understanding rests on a single in vitro receptor study, one mouse behavioral study, and pooled poison center surveillance.
History[edit]
History
Discovery
Δ10-THC was first generated in 1984 at the Hebrew University of Jerusalem, where Srebnik, Lander, Breuer, and Mechoulam demonstrated that base-catalyzed isomerization of THC could shift the cyclohexene double bond to multiple ring positions, including the Δ10 position.[2] The compound was not the primary target of that work — the paper focused on other THC isomers — and no pharmacological characterization followed. For over three decades, Δ10-THC remained a catalogued chemical curiosity with no receptor binding, behavioral, or human studies.
Rediscovery and commercialization
Around 2019–2020, Fusion Farms, a California cannabis extraction company, purchased outdoor biomass contaminated with aerial fire retardant during the state's wildfire season. Unusual crystals that formed during distillation matched no known cannabinoid reference standard; organic chemist Josh Jones identified them via NMR spectroscopy as Δ10-THC and developed a scalable synthesis using food-grade acid catalysts.[3] The compound's commercial trajectory was enabled by the 2018 US Farm Bill, which legalized hemp-derived products containing less than 0.3% Δ9-THC by dry weight.
Present status
By 2023, Δ10-THC had become one of the six most prevalent intoxicating compounds in the US hemp-derived cannabinoid market, appearing in vapes, edibles, and blended formulations.[4] This rapid market adoption occurred in near-complete absence of pharmacological, toxicological, or clinical data — a pattern shared with Δ8-THC and other hemp-derived cannabinoids.[7]
The name "Δ10-THC" follows standard cannabinoid nomenclature, indicating the position of the double bond in the cyclohexene ring — C10–C10a rather than C9–C10 (Δ9-THC) or C8–C9 (Δ8-THC). The compound has no established street names and circulates commercially under its chemical abbreviation.
Chemistry[edit]
Chemistry
Structural identity
Δ10-THC belongs to the terpenophenolic cannabinoid class, sharing the dibenzopyran core and C5 alkyl side chain common to all classical cannabinoids. It is a positional isomer of Δ9-THC, differing only in the location of the double bond within the cyclohexene ring: C10–C10a in Δ10-THC versus C9–C10 in Δ9-THC. This single-bond migration produces measurably different receptor binding and functional pharmacology.
| Molecular formula | C₂₁H₃₀O₂ |
| Molecular weight | 314.5 g/mol |
The molecular formula and weight are identical to those of Δ9-THC and Δ8-THC — all three share the same C₂₁H₃₀O₂ skeleton. Differentiation requires chromatographic or spectroscopic methods such as HPLC, NMR, or tandem mass spectrometry.
Stereochemistry
Δ10-THC has two chirality centers (C6a and C9), producing two diastereomers:
- ''trans-Δ10-THC''' — (6aR,9R) configuration. The more pharmacologically active form and the predominant isomer in commercial products.[1][8]
- ''cis-Δ10-THC''' — (6aR,9S) configuration. Approximately tenfold less active at CB1.[1]
Physical properties
No published melting point, solubility, or vapor pressure data exist for Δ10-THC. As a terpenophenolic cannabinoid, it is expected to be a viscous oil at room temperature, highly lipophilic, and poorly water-soluble. Δ8-THC is noted to be more chemically stable than Δ9-THC;[9] the relative stability of Δ10-THC has not been characterized.
Pharmacology[edit]
Pharmacology
Mechanism of action
Δ10-THC interacts with the endocannabinoid system through both CB1 and CB2 receptors, but its functional behavior diverges sharply from every other characterized THC isomer. The sole published in vitro study found that both the trans and cis isomers bind CB1 but act as antagonists — blocking receptor activation rather than producing it — at concentrations up to 10 μM.[1] This is unprecedented among THC isomers; Δ9-THC, Δ8-THC, and Δ6a,10a-THC all function as partial agonists at CB1.
The trans isomer blocked CB1 activation with moderate potency; the cis isomer showed weaker antagonism.[1] This in vitro profile sits in unresolved tension with animal data: Wiley et al. found that Δ10-THC partially substituted for Δ9-THC in a mouse drug discrimination test, but only at the very high dose of 100 mg/kg — a dose that also significantly depressed response rates.[8]
Possible explanations include formation of active metabolites in vivo, psychoactive mechanisms that do not depend on CB1, or context-dependent differences between in vitro and in vivo signaling. Whether Δ10-THC produces its effects in humans through CB1, CB2, or alternative mechanisms is not established. The compound's fundamental pharmacological identity — agonist, antagonist, or context-dependent modulator — remains an open question.
Pharmacokinetics
No pharmacokinetic studies have been published for Δ10-THC in humans or animals. All parameters below are projections from Δ9-THC and must not be treated as measured values.[10] inferred
By analogy to Δ9-THC, inhaled bioavailability is estimated at 10–35%, with peak plasma levels expected within 6–10 minutes. Oral bioavailability is estimated at 4–12%. Metabolism likely proceeds through liver enzymes shared with Δ9-THC, producing hydroxylated and carboxylated metabolites. Plasma half-life ranges from 1–3 days in occasional users to 5–13 days in chronic users.
The absence of any pharmacokinetic characterization — even basic plasma concentration-time curves — represents a critical data gap for a compound in widespread commercial use.
Neuroscience[edit]
Neuroscience
Where it acts
Classical cannabinoid psychoactivity operates through CB1 receptors on presynaptic terminals, where endocannabinoids function as retrograde signaling molecules to suppress neurotransmitter release — particularly GABA and glutamate — across hippocampal, prefrontal, amygdalar, and basal ganglia circuits. These circuit-level effects produce the characteristic cannabinoid profile: impaired short-term memory, altered time perception, appetite stimulation, and context-dependent mood shifts.
Δ10-THC's demonstrated CB1 antagonist activity[1] complicates direct application of this framework. A CB1 antagonist would be predicted to oppose classical cannabinoid neural effects — increasing neurotransmitter release, potentially producing anxiety rather than relaxation, and suppressing rather than enhancing appetite. That anecdotal reports describe mild euphoria suggests either in vivo metabolic conversion, CB2-mediated effects, or dose-dependent switching between antagonist and weak partial agonist behavior.
Why it matters
If Δ10-THC functions as a low-potency CB1 antagonist in vivo, it may modulate endocannabinoid tone — the baseline level of endocannabinoid signaling that regulates stress response, appetite, and mood — without the dramatic disruption caused by high-potency antagonists. This could explain its reported milder, more stimulating experiential character compared to CB1 agonists like Δ9-THC.
The entourage effect hypothesis adds a further dimension: because Δ10-THC is rarely consumed in isolation — commercial products frequently blend it with Δ8-THC, Δ9-THC, and other cannabinoids[4] — it may modulate co-consumed agonists, potentially attenuating anxiety while preserving euphoria through alternative mechanisms.
The central unresolved puzzle is the disconnect between in vitro CB1 antagonism[1] and in vivo Δ9-THC-like behavioral effects at extreme doses.[8] Until this is resolved in human-relevant systems, mechanism-based predictions remain unreliable.
Subjective Effects[edit]
Subjective Effects
The experiential character of Δ10-THC remains poorly defined and may not follow the classical cannabinoid template. Its CB1 antagonist profile in vitro[1] predicts effects qualitatively different from Δ9-THC — potentially stimulating rather than sedating, memory-sparing rather than amnestic, and appetite-neutral rather than appetite-enhancing. Anecdotal reports broadly align, describing a mild, clear-headed euphoria with less anxiety than Δ9-THC. Route of administration, product composition, and individual endocannabinoid tone likely modulate the experience substantially.
Among THC isomers, Δ10-THC is reported as milder than both Δ9-THC and Δ8-THC, with an energizing quality users compare to sativa-type cannabis rather than the heavier sedation typical of indica-associated profiles. Its pharmacological distinctiveness — antagonism rather than agonism at CB1 — suggests it may occupy a fundamentally different experiential category than its isomers, though controlled human data to confirm this remain absent.
Timeline
Slow gastrointestinal absorption delays first effects to 30–90 minutes post-ingestion. Initial awareness is subtle — a mild shift in mood or slight perceptual change that may be difficult to distinguish from placebo.
Gradual intensification over 1–2 hours as absorption continues. Effects build slowly and unevenly. Mild cognitive euphoria, emerging stimulation, and increasing body awareness develop.
Maximum intensity 2–4 hours post-ingestion. The full effect profile emerges — cognitive euphoria, mild time alteration, stimulation, and physical effects including dry mouth and possible tachycardia. Reported as milder and more clear-headed than oral Δ9-THC.
Gradual decline over 2–4 hours. Cognitive effects diminish before physical effects. Residual dry mouth, mild fatigue, and subtle appetite changes may linger as the experience resolves.
Residual effects may persist for several hours — subtle mood changes, mild physical fatigue, or lingering appetite shifts. Cognitive function returns to near-baseline but subclinical impairment may remain longer than perceived.
⚠ Do not drive or operate heavy machinery for at least 8 hours after oral use.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- No data
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 21 days
- Physical
- Low
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- Δ9-THC · Δ8-THC · other CB1 receptor agonists
Safety
Toxicity
No lethal dose has been established for Δ10-THC in any species. No deaths attributable to Δ10-THC alone appear in published literature, and no therapeutic index can be calculated.
Acute toxicity: The only clinical toxicity data come from US poison center surveillance. Burgess et al. reported 5,022 combined exposures to Δ8-THC, Δ10-THC, and THC-O acetate during 2021–2022.[5] Δ8-THC accounted for 98.1% of cases; the Δ10-THC fraction was not separately quantified. The pooled presentation included:
- CNS depression: 25% of cases
- Rapid heart rate: 23%
- Agitation: 15.6%
- Serious medical outcome: 38.4%
Children under six represented 30.1% of all exposures (peak age: 2 years), with ingestion accounting for 94.2% — consistent with accidental consumption of edible products. These figures predominantly reflect Δ8-THC toxicity and cannot be directly attributed to Δ10-THC. safety citation needed
Pulmonary concerns: Δ10-THC is increasingly present in cannabis vape products.[11][12] No pulmonary toxicology data exist for Δ10-THC vapor specifically. General cannabis vaping risks apply — the EVALI epidemic was primarily linked to vitamin E acetate as a diluent, but other additives and breakdown products in hemp-derived vaporizers remain poorly studied.
Product contamination: All commercial Δ10-THC is produced via acid-catalyzed CBD isomerization, a process known to generate uncharacterized iso-THC isomers and byproducts,[13] residual solvents and heavy metals from inadequate purification,[6] and significant gaps between labeled and actual cannabinoid concentrations.[6][4] No study has specifically profiled Δ10-THC product impurities — the risk is inferred from shared manufacturing chemistry. safety citation needed
Psychological Risks
No controlled studies have evaluated the psychological risk profile of Δ10-THC. Agitation appeared in 15.6% of pooled poison center cases (predominantly Δ8-THC).[5] Anecdotal reports describe less anxiety and paranoia than Δ9-THC, but this has not been tested under controlled conditions.
The compound's CB1 antagonist profile raises a theoretical concern: rimonabant, a potent CB1 antagonist, was withdrawn from the European market after association with depression, anxiety, and suicidal thoughts. Whether Δ10-THC's much weaker CB1 antagonism carries any analogous psychiatric risk is unknown, but the pharmacological class parallel warrants monitoring. safety citation needed
No data exist on HPPD (HPPD), psychosis precipitation, or psychiatric destabilization risk specific to Δ10-THC.
Tolerance & Dependence
No tolerance or dependence data exist for Δ10-THC in any species. The closest structural analog with published data is Δ8-THC, which produces tolerance via CB1 receptor downregulation, cross-tolerance to synthetic cannabinoids, and physical dependence in mice.[14] Cannabis broadly carries moderate dependence risk with a 2–6 day withdrawal — irritability, sleep disruption, appetite changes, and craving.[15]
Whether Δ10-THC produces classical cannabinoid tolerance and dependence is an open question. If its CB1 antagonist profile holds in vivo, the standard mechanism of cannabinoid tolerance — receptor downregulation from sustained agonist exposure — would not apply. An antagonist would not be expected to produce tolerance or physical dependence through this pathway.
Drug Interactions
No published drug interaction data exist for Δ10-THC. All interactions below are inferred from cannabinoid class pharmacology. inferred
CNS depressant potentiation: Co-use with alcohol, benzodiazepines, opioids, or other CNS depressants is expected to produce additive sedation and impaired coordination. Rapid heart rate documented in 23% of pooled adverse events[5] may compound cardiovascular strain from stimulant co-use.
Liver enzyme competition: By structural analogy to Δ9-THC, Δ10-THC is presumed to be metabolized via CYP3A4 and CYP2C9.[10] Competition at these enzymes could alter blood levels of co-administered medications, including blood thinners (warfarin via CYP2C9), certain antidepressants, immunosuppressants, and antiviral drugs.
Blood thinner interaction: The shared CYP2C9 pathway with warfarin means cannabinoid-anticoagulant interactions resulting in elevated bleeding risk have been documented for Δ9-THC products; the same risk is presumed for Δ10-THC. safety citation needed
Antipsychotic interactions: If Δ10-THC functions as a CB1 antagonist in vivo, its interaction with antipsychotics may differ from Δ9-THC. CB1 antagonism combined with dopamine D2 antagonism could produce unpredictable effects in the endocannabinoid-dopamine system. No data exist.
Contraindications
No substance-specific contraindication data exist for Δ10-THC. The following are derived from cannabinoid class pharmacology and limited adverse event data.
Pregnancy and breastfeeding (absolute): No reproductive toxicity data exist. Cannabinoids as a class cross the placental barrier and are excreted in breast milk. Avoidance is the standard recommendation. safety citation needed
Pediatric exposure (absolute): Children under six represented 30.1% of poison center cases in the combined Δ8/Δ10/THC-O dataset, with serious medical outcomes in 38.4%.[5] Products must be stored out of reach of children.
Heart conditions (relative): Rapid heart rate occurred in 23% of pooled adverse events.[5] Individuals with pre-existing heart rhythm problems, coronary artery disease, or heart failure face elevated risk.
Blood thinner therapy (relative): Presumed CYP2C9 competition with warfarin and related blood thinners. Monitoring is advisable if co-use occurs. safety citation needed
Psychiatric vulnerability (relative): The theoretical CB1 antagonist/rimonabant parallel warrants caution in individuals with depression, anxiety disorders, or history of suicidal thoughts. No data confirm or refute this risk. safety citation needed
Driving and machinery (relative): No impairment studies exist. General cannabinoid impairment risk applies. Cross-reactivity with standard urine drug screens[16] means use may produce positive workplace drug tests regardless of actual impairment.
Harm Reduction[edit]
Forms & Identification
Δ10-THC products exist in an unregulated manufacturing space where label accuracy is unreliable. Certificates of analysis from third-party labs offer some assurance, but documented discrepancies between declared and actual cannabinoid content mean even tested products may not contain what they claim.[6][4]
Because Δ10-THC is produced via the same acid-catalyzed isomerization as Δ8-THC, products may contain unknown byproducts and residual solvents that standard cannabinoid panels do not screen for.[13] Look for full-panel third-party testing that includes residual solvents, heavy metals, and pesticides — not just cannabinoid potency.
Guidelines
- Obtain products with full-panel third-party testing including residual solvents and heavy metals — not cannabinoid potency alone
- Start with the lowest available dose and wait for full onset before considering additional use
- With edibles, allow at least 90 minutes before any additional consumption
- Avoid driving or operating machinery — no impairment studies exist, and standard drug screens detect THC isomers[16]
- Keep all products stored securely away from children — pediatric accidental ingestion is the most common exposure route in poison center data[5]
- If using vape products, avoid cartridges with added cutting agents or unknown ingredients
Set & Setting
Δ10-THC is typically described as milder than Δ9-THC, but product variability and the absence of standardized dosing make actual intensity unpredictable. Start with a low amount and wait for full onset before redosing — edibles in particular have delayed and variable onset.
A calm, familiar environment with trusted company is advisable for first use. The compound's effects in combination with other cannabinoids (common in blended products) may differ from isolated Δ10-THC.
Aftercare & integration. Δ10-THC experiences are generally mild and do not typically require formal integration. If lingering anxiety, mood disturbance, or sleep disruption follows use, basic recovery steps apply: hydrate, eat a balanced meal, and rest in a calm environment.
For individuals who experienced an unexpectedly intense or distressing reaction — particularly from edible products where dosing is imprecise — talking through the experience with a trusted person may help resolve residual unease. Persistent anxiety or mood changes lasting more than a few days warrant consultation with a healthcare provider.
Recovery & Support
No dependence data exist specifically for Δ10-THC, but individuals who find themselves using cannabinoid products compulsively or experiencing difficulty stopping should consider the broad resources available for cannabis use concerns. SAMHSA's National Helpline (1-800-662-4357) offers free, confidential referrals. Marijuana Anonymous and SMART Recovery provide peer support frameworks.
Cannabis withdrawal, when it occurs, typically resolves within 2–6 days and involves irritability, sleep disruption, appetite changes, and craving.[15] Professional support can help manage these symptoms and address underlying patterns.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most Δ10-THC adverse events involve manageable discomfort — elevated heart rate, anxiety, or sedation. Seek immediate medical help if any of the following occur:
- Chest pain or severe heart pounding
- Loss of consciousness or inability to be roused
- Seizures
- Severe breathing difficulty
- Extreme agitation with risk of self-harm
Immediate steps:
- Call emergency services if any of the above signs are present
- Move the person to a quiet, safe space
- If unconscious but breathing, place in the recovery position (on their side)
- Do not induce vomiting if the substance was ingested
- Monitor breathing and heart rate until help arrives
What to tell the dispatcher: Name the substance (Δ10-THC or "a hemp-derived THC product"), estimated amount consumed, time of consumption, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
Legal Status
Δ10-THC occupies a contested legal space internationally. Its status depends on whether jurisdictions control tetrahydrocannabinols generically — capturing all positional isomers — or list only specific THC variants. In the United States, the distinction between "hemp-derived" and "synthetically derived" cannabinoids creates additional ambiguity unique to the post-2018 Farm Bill landscape.[17]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Contested — Schedule I if synthetically derived; potentially legal if hemp-derived | The 2018 Farm Bill legalized hemp-derived cannabinoids with less than 0.3% Δ9-THC by dry weight. The DEA's April 2026 rescheduling order explicitly excludes tetrahydrocannabinols "derived only through artificial synthesis" from Schedule III reclassification, citing Δ10-THC as an example.[18] Whether CBD-to-Δ10-THC conversion constitutes "synthesis" is actively contested.[7] |
| United States (state) | Variable — approximately 30+ states permit; 15+ states ban | States including Alaska, Arizona, Colorado, Hawaii, Idaho, Iowa, Montana, Nevada, and Utah have explicitly banned Δ10-THC or all chemically converted cannabinoids. State laws change frequently. Online retailers frequently ship regardless of local restrictions.[19] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | All THC stereoisomers and structural isomers are controlled. Δ10-THC is unambiguously controlled. |
| European Union | Controlled (generic THC scheduling) | THC and its isomers are controlled across EU member states. Δ10-THC falls under generic cannabinoid control in virtually all jurisdictions. |
| Canada | Controlled (Cannabis Act / CDSA Schedule II) | All tetrahydrocannabinols are controlled generically. No legal pathway for commercial Δ10-THC products outside the regulated cannabis framework. |
| Australia | Controlled (Poisons Standard, Schedule 8) | Cannabinoid analogs are controlled under generic scheduling. Not available for commercial sale without TGA authorization. |
Analog and conversion considerations
The central legal question in the United States is whether acid-catalyzed isomerization of CBD to Δ10-THC constitutes "synthetic" production. The hemp industry argues that converting one naturally occurring cannabinoid to another does not meet the definition of synthesis; federal regulators have signaled the opposite interpretation.
This question has not been definitively resolved by federal courts as of May 2026. The regulatory trajectory across US states is toward increasing restriction of chemically converted cannabinoids.[7][17]
references
- [1]
- [2] ^abSrebnik M, Lander N, Breuer A, Mechoulam R (1984) Base-catalysed double-bond isomerizations of cannabinoids: structural and stereochemical aspects — Journal of the Chemical Society, Perkin Transactions 1 doi:10.1039/p19840002881
- [3]
- [4]
- [5]
- [6] ^abcdRay CL, Bylo MP, Pescaglia J, Gawenis JA, Greenlief CM (2022) Delta-8 Tetrahydrocannabinol Product Impurities — Molecules doi:10.3390/molecules27206924